Retina Microvascularisation and Cardiovascular Heart Disease Prediction

NCT ID: NCT01027988

Last Updated: 2013-10-30

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 40 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2009-09-30
• Study Completion Date: 2013-10-31

Brief Summary

Earlier studies have found that retinal photography could be very useful for evaluating the condition of microcirculation and the risk of cardiovascular diseases in patients. The architectural changes in retinal vascularisation strongly correlates with macrovascular remodeling. Also, recent founding suggests a possible close anatomical parallel between both the macrovascular and the microvascular blood.

Our objectives are to assess (1) in which age and sex subgroups, if any, retinal vascular alteration in arterioles and venules can be predictive for cardiovascular morbidity and mortality; and (2) whether variations in arteriolar or venular caliber will predict better cardiovascular pathogenesis in normal and patient population. If the association between the diameter of the retinal vessels and the risks of cardiovascular disease is verified during this study, the impact on prevention would be enormous. The retinal microvascular change could become a powerful biomarker in the early detection of the cardiovascular pathogenesis and death risk

Conditions

Cardiovascular Disease

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Age between 50 to 70 years old (male/female)
• indication of coronarography within the last 3 month preceding the enrollment
• Patients with history of stroke, heart failure or arteriosclerosis.
• At least one of the following risk factors for cardiovascular complication:

• Hypertension
• Coronary heart disease (CHD)
• Diabetes
• Structural heart disease
• Dyslipidemia
• Obesity

Exclusion Criteria

• Patients with a permanent pacemaker or ICD
• Nephrosis or chronic renal failure
• The study interferes with therapeutic or diagnostic procedures
• Patients with inability to consent or comply with follow up requirements
• Patients with glaucoma
• Patients with any retina degeneration disease vascular age-related macular degeneration or any -retina degeneration disease
• Patients who are pregnant

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fonds de la Recherche en Santé du Québec

OTHER_GOV

Sponsor Role: collaborator

Montreal Heart Institute

OTHER

Sponsor Role: lead

Responsible Party

Bernard Thibault

Cardiologist - Electrophysiologist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Bernard Thibault, MD

Role: PRINCIPAL_INVESTIGATOR

Montreal Heart Institute

Locations

Montreal Heart Institute, 5000 Belanger Street

Montreal, Quebec, Canada

Countries

Canada

Other Identifiers

ICM 08-1050

Identifier Type: -

Identifier Source: org_study_id